Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Non-myeloablative Stem Cell Transplants

Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effective graft-versus-leukemia effect after allogeneic stem cell transplantation in murine lymphocytic leukemia

Bone Marrow Transplantation volume 31, pages 11–15 (2003)Cite this article

Summary:

Graft-versus-host disease (GVHD) is a severe disorder and despite therapeutic efforts to decrease its distressing clinical manifestations, treatment is still not optimal. Here we report the results of studies, in which the purine analogue, fludarabine phosphate, was used in an attempt to modify and decrease GVHD after stem cell transplantation, across major histocompatibility barriers for murine leukemia. B-cell leukemia (BCL-1) bearing (BALB/c×C57BL/6) F1 mice received two cycles of fludarabine (0.8 mg/kg) for 5 days every 2 weeks, followed by 400 mg/kg cyclophosphamide i.p. Animals were then transplanted with C57BL/6 precursor cells and the development of leukemia and extent of GVHD was monitored both clinically and histopathologically. In the fludarabine-treated group, only nine of 28 (32%) mice developed leukemia, compared to 25 of 33 (76%) of control animals (P=0.0006 ). Mice treated with fludarabine-containing regimens prior to transplantation also had much less GVHD both clinically and at autopsy, while graft-versus-leukemia appeared to be augmented in the same animals.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Sorensen JM, Vena DA, Fallavollita A et al. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five year follow-up report. J Clin Oncol 1997; 15: 458–465.

    Article  CAS  PubMed  Google Scholar 

  2. Foran JM, Oscier D, Orchard J et al. Pharamacokinetic study of single doses of oral fludarabine phosphate in patients with “low-grade” non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol 1999; 17: 1574–1579.

    Article  CAS  PubMed  Google Scholar 

  3. Johnson S, Smith AG, Loffler H et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide doxorubicin, and prednisone (CAP) for treatment of advanced stage chronic lymphocyte leukemia The French Cooperative Group on CLL. Lancet 1996; 347: 1432–1438.

    Article  CAS  PubMed  Google Scholar 

  4. Ghandi V, Estey E, Keating MJ, Plunkett W . Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993; 11: 116–124.

    Article  Google Scholar 

  5. Ghandi V, Plunkett W, Weller S et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics in leukemia cells. J Clin Oncol 2001; 19: 2142–2152.

    Article  Google Scholar 

  6. Yalman N, Sarper N, Devecioglu O et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Turk J Pediatr 2000; 42: 198–204.

    CAS  PubMed  Google Scholar 

  7. Koller CA, Kantarjian HM, Feldman EJ et al. A phase I–II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia. Cancer 1999; 86: 2246–2251.

    Article  CAS  PubMed  Google Scholar 

  8. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  PubMed  Google Scholar 

  9. Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New Engl J Med 1998; 339: 1186–1193.

    Article  CAS  PubMed  Google Scholar 

  10. Borhnauser M, Thiede C, Schuler U et al. Dose-reduced conditioning for allogeneic blood stem transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant 2000; 26: 119–125.

    Article  Google Scholar 

  11. Priebe T, Platsoucas CD, Seki H et al. Purine nucleoside modulation of functions of human lymphocytes. Cell Immunol 1990; 129: 321–328.

    Article  CAS  PubMed  Google Scholar 

  12. Chun HG, Leyland-Jones B, Cheson BD . Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991; 9: 175–188.

    Article  CAS  PubMed  Google Scholar 

  13. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824.

    Article  CAS  PubMed  Google Scholar 

  14. Petrus MJ, Williams JF, Eckhaus MA et al. An immuno-ablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD. Biol Blood Marrow Transplant 2000; 6: 182–189.

    Article  CAS  PubMed  Google Scholar 

  15. Goodman ER, Fiedor PS, Fein S et al. Fludarabine phosphate: a DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity. Am Surg 1996; 62: 435–442.

    CAS  PubMed  Google Scholar 

  16. Or R, Weiss L, Amir G et al. The prophylactic potential of fludarabine monophosphate in graft-versus-host disease after bone marrow transplantation in murine models. Bone Marrow Transplant 2000; 25: 263–266.

    Article  CAS  PubMed  Google Scholar 

  17. Slavin S, Strober S . Spontaneous murine B-cell leukemia. Nature 1978; 272: 624–626.

    Article  CAS  PubMed  Google Scholar 

  18. Briz M, Cabrera R, Sanjuan I et al. Diagnosis of transfusion-associated graft-versus-host disease by polymerase chain reaction in fludarabine-treated B-chronic lymphocytic leukemia. Br J Haematol 1995; 91: 409–411.

    Article  CAS  PubMed  Google Scholar 

  19. Wijermans PW, Gerrits WB, Haak HL . Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993; 50: 292–296.

    Article  CAS  PubMed  Google Scholar 

  20. Nagler A, Slavin S, Varadi G et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021–1028.

    Article  CAS  PubMed  Google Scholar 

  21. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral blood stem-cell transplantation. New Engl J Med 2000; 343: 750–758.

    Article  CAS  PubMed  Google Scholar 

  22. Wasch R, Reisser S, Hahn J et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantation. Bone Marrow Transplant 2000; 26: 243–250.

    Article  CAS  PubMed  Google Scholar 

  23. Luznik L, Jalla S, Engstrom LW et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001; 98: 3456–3464.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Bone Marrow Transplantation and Cancer Immunobiology Research Laboratory, Jerusalem, Israel

    L Weiss, A Abdul-Hai & R Or

  2. Department of Pathology, Jerusalem, Israel

    G Amir

  3. Department of Hematology, Hadassah University Hospital and Hebrew University, Hadassah Medical School, Jerusalem, Israel

    A Polliack

Authors
  1. L Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Abdul-Hai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Or
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Amir
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Polliack
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weiss, L., Abdul-Hai, A., Or, R. et al. Fludarabine in combination with cyclophosphamide decreases incidence of GVHD and maintains effective graft-versus-leukemia effect after allogeneic stem cell transplantation in murine lymphocytic leukemia. Bone Marrow Transplant 31, 11–15 (2003). https://doi.org/10.1038/sj.bmt.1703775

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703775

Keywords

This article is cited by

Search

Advanced search

Quick links